Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
NCT01810458 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 109
Last updated 2023-08-21
Summary
We hypothesize that individuals with Alpha-1 Antitrypsin (AAT) deficiency have ongoing liver injury which is not detected by the usual blood tests used to look at liver function. This ongoing liver injury leads to cirrhosis in a significant number of adults with AAT deficiency.
Conditions
- Liver Fibrosis
- Alpha-1 Antitrypsin Deficiency
- AAT Deficiency
- AATD
Interventions
- DEVICE
-
Abdominal ultrasound
Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
- PROCEDURE
-
History and physical
Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
- PROCEDURE
-
Intravenous catheter
Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
- PROCEDURE
-
Blood draw
At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
- OTHER
-
Liver questionnaire
At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
- PROCEDURE
-
Liver Biopsy
Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
- DRUG
-
Midazolam
Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
- DRUG
-
Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
- DRUG
-
Lidocaine
Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
- DRUG
-
Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
- DRUG
-
Lorazepam
Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
- DRUG
-
Oxycodone/Acetaminophen
Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
- DRUG
-
Ondansetron
Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Sponsors & Collaborators
-
University of Florida
lead OTHER
Principal Investigators
-
Mark Brantly, MD · University of Florida
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2019-09-30
- Completion
- 2019-09-30
Countries
- United States
Study Locations
More Related Trials
-
Phase Angle and Mortality in Patients With Cirrhosis
NCT02023177 ·Status: COMPLETED
-
Biomarkers in Liver Failure
NCT02833064 ·Status: ACTIVE_NOT_RECRUITING
-
Natural History of Noncirrhotic Portal Hypertension
NCT02417740 ·Status: RECRUITING
-
Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions
NCT03172650 ·Status: UNKNOWN
-
Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects
NCT05249374 ·Status: COMPLETED ·Phase: PHASE1
-
The Liver Care Trial
NCT05855031 ·Status: RECRUITING ·Phase: NA
-
An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)
NCT05146882 ·Status: WITHDRAWN ·Phase: PHASE2
-
Breath Test for Patients With Acute Liver Disease for Early Detection of the Need for Transplant or Recovery
NCT01435421 ·Status: UNKNOWN
-
Comparative Study of Novel Prognostic Scores in Patients With Liver Cirrhosis
NCT07238543 ·Status: NOT_YET_RECRUITING
-
Short Term Outcomes in Hospitalized Patients With Liver Cirrhosis
NCT05848414 ·Status: COMPLETED
-
Acute-On-Chronic Liver Failure In Cirrhotic Patients
NCT04790435 ·Status: COMPLETED
-
Impact of Dietary Assessment and Intervention on Outcomes in Liver Cirrhosis Patients
NCT05259930 ·Status: RECRUITING ·Phase: NA
-
Haemostatic Imbalance in Patients With Chronic Liver Disease
NCT03589430 ·Status: UNKNOWN
-
Mechanism of TIPS to Improve Sarcopenia
NCT06794853 ·Status: RECRUITING
-
Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.
NCT03241823 ·Status: UNKNOWN
-
Utility of Renal Biomarkers in Cirrhosis
NCT01217983 ·Status: COMPLETED
-
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
NCT05213598 ·Status: RECRUITING
-
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
NCT03056612 ·Status: COMPLETED
-
Acute Liver Injury in Patients With Pneumonia
NCT06103981 ·Status: NOT_YET_RECRUITING
-
Proton Pump Inhibitors and Dysbiosis in Cirrhosis
NCT01458990 ·Status: COMPLETED ·Phase: NA
-
Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis
NCT03508388 ·Status: TERMINATED
-
Kidney Affection in Non Alcaholic Fatty Liver Diseases
NCT04273230 ·Status: COMPLETED
-
Hypertriglyceridemia-associated Acute Pancreatitis: Apheresis Vs. Conservative Treatment
NCT04708925 ·Status: COMPLETED
-
Role of Bilirubin Molecular Species in Hepatic Encephalopathy and Acute-on-chronic Liver Failure
NCT05566548 ·Status: UNKNOWN
-
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
NCT04210245 ·Status: COMPLETED ·Phase: PHASE2